SCHEMBL13429166

SCHEMBL13429166

O=c1cc(Oc2ccc(-c3cn[nH]c3)cc2)c2ccccc2[nH]1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKT1 P31749 1/20 0.43
AKT2 P31751 1/20 0.43
TUBB4A P04350 2/20 0.42
TUBB P07437 2/20 0.42
TUBA3C P0DPH7 2/20 0.42
TUBA1B P68363 2/20 0.42
TUBA4A P68366 2/20 0.42
TUBB4B P68371 2/20 0.42
TUBB3 Q13509 2/20 0.42
TUBB2A Q13885 2/20 0.42
TUBB8 Q3ZCM7 2/20 0.42
TUBA3E Q6PEY2 2/20 0.42
TUBA1A Q71U36 2/20 0.42
TUBA1C Q9BQE3 2/20 0.42
TUBB6 Q9BUF5 2/20 0.42
TUBB2B Q9BVA1 2/20 0.42
TUBB1 Q9H4B7 2/20 0.42
HPGD P15428 1/20 0.41
MAPK1 P28482 1/20 0.41
HTT P42858 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13429158 0.88 HPGD (0.43) AKT1AKT2TUBB4ATUBBTUBA3C
SCHEMBL13429131 0.88 ROCK2 (0.43) AKT1AKT2FLT3PIK3CAPIK3CB
SCHEMBL13429165 0.86 FLT3 (0.48) AKT1AKT2HPGDSMN1; SMN2FLT3
SCHEMBL13429113 0.85 HPGD (0.57) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL13429178 0.83 HPGD (0.44) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL13429004 0.82 CTSV (0.50) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL13429118 0.82 HPGD (0.45) HPGDMAPK1HTTSMN1; SMN2CYP1A2
SCHEMBL13429115 0.81 HPGD (0.51) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL13429155 0.80 CCNC (0.47) HPGDMAPK1HTTSMN1; SMN2FLT3
SCHEMBL2008835 0.79 HPGD (0.54) HPGDMAPK1HTTSMN1; SMN2CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100068204-A1 4-ARYLOXYQUINOLIN-2(1H)-ONES AS MTOR KINASE AND PI3 KINASE INHIBITORS, FOR USE AS ANTI-CANCER AGENTS WYETH (US) 2010-03-18 US disclosed
US-20100068204-A1 4-ARYLOXYQUINOLIN-2(1H)-ONES AS MTOR KINASE AND PI3 KINASE INHIBITORS, FOR USE AS ANTI-CANCER AGENTS WYETH (US) 2010-03-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100068204-A1 4-ARYLOXYQUINOLIN-2(1H)-ONES AS MTOR KINASE AND PI3 KINASE INHIBITORS, FOR USE AS ANTI-CANCER AGENTS MTOR, RICTOR, PIK3CA AKT1 16/4885AKT2 14/4885TUBB4A 2579/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.